

September 2, 2025

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our intimation to stock exchanges on June 21, 2024, regarding the exit from our manufacturing site, we wish to inform you that AstraZeneca Pharma India Limited ('the Company') has surrendered its manufacturing license, which was valid up to December 2027, to the Drugs Controller and Licensing Authority for cancellation.

We request you to take the above intimation on record.

For **AstraZeneca Pharma India Limited**

Manasa. R

Company Secretary